Literature DB >> 21734210

The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money.

William H Shrank1, Niteesh K Choudhry, Joshua N Liberman, Troyen A Brennan.   

Abstract

In this article we highlight the important role that medication therapy can play in preventing disease and controlling costs. Focusing on coronary artery disease, we demonstrate that prevention, with the appropriate use of generic medications, appears far more cost-effective than previously documented, and it may even save on costs. For example, an earlier study estimated that reducing blood pressure to widely established clinical guidelines in nondiabetic patients cost an estimated $52,983 per quality-adjusted life-year if a brand-name drug was used. However, we estimate that the cost is just $7,753 per quality-adjusted life-year at generic medication prices. As the nation attempts to find strategies to improve population health without adding to the unsustainably high cost of care, policy makers should focus on ensuring that patients have access to essential generic medications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734210     DOI: 10.1377/hlthaff.2010.0431

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  11 in total

1.  The Present and the Future of Cost-Related Non-Adherence in Medicare Part D.

Authors:  William H Shrank; Jennifer M Polinski
Journal:  J Gen Intern Med       Date:  2015-08       Impact factor: 5.128

2.  The economic impact of the transition from branded to generic oncology drugs.

Authors:  W Y Cheung; E A Kornelsen; N Mittmann; N B Leighl; M Cheung; K K Chan; P A Bradbury; R C H Ng; B E Chen; K Ding; J L Pater; D Tu; A E Hay
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

3.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

4.  Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).

Authors:  Md Motiur Rahman; Yasser Alatawi; Ning Cheng; Jingjing Qian; Annya V Plotkina; Peggy L Peissig; Richard L Berg; David Page; Richard A Hansen
Journal:  Epilepsy Res       Date:  2017-06-13       Impact factor: 3.045

5.  Efficacy of Generic Granisetron vs Kytril® for PONV in Major Gynecological Operations: A Randomized, Double-blind Clinical Trial.

Authors:  Ashraf Aleyasin; Somayeh Hanafi; Elham Saffarieh; Hassan Torkamandi; Sara Allahyari; Fariborz Sadeghi; Mohammadreza Javadi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

Review 6.  Generic versus brand-name drugs used in cardiovascular diseases.

Authors:  Lamberto Manzoli; Maria Elena Flacco; Stefania Boccia; Elvira D'Andrea; Nikola Panic; Carolina Marzuillo; Roberta Siliquini; Walter Ricciardi; Paolo Villari; John P A Ioannidis
Journal:  Eur J Epidemiol       Date:  2015-11-30       Impact factor: 8.082

7.  Generic antiepileptic drug prescribing: a cross-sectional study.

Authors:  Jennifer Meyer; David Fardo; Steven T Fleming; Claudia Hopenhayn; Yevgeniya Gokun; Melody Ryan
Journal:  Epilepsy Behav       Date:  2012-11-23       Impact factor: 3.337

8.  Generic drugs: Review and experiences from South India.

Authors:  Philip Mathew
Journal:  J Family Med Prim Care       Date:  2015 Jul-Sep

9.  Medicaid prescription limits: policy trends and comparative impact on utilization.

Authors:  Daniel A Lieberman; Jennifer M Polinski; Niteesh K Choudhry; Jerry Avorn; Michael A Fischer
Journal:  BMC Health Serv Res       Date:  2016-01-15       Impact factor: 2.655

10.  Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.

Authors:  Olivier J Wouters; Panos G Kanavos; Martin McKEE
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.